StockData
Supernus, Inc. logo

Supernus, Inc. (SUPN) stock

SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30
$29.04+0.21 (+0.73%)

Close on Nov 17, 2026Market cap $3.43BP/E 8.1Yield –

Supernus operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Supernus's operating income for the twelve months ending Sep 30, 2026 was $558.00M, up 145.8% year over year. For fiscal 2025 it was $262.00M, up 589.5% from the year before. The highest annual figure on record is $262.00M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$262.00M+589.5%
FY2024Dec 31, 2024$38.00M–
FY2023Dec 31, 2023-$152.00M–
FY2022Dec 31, 2022-$77.00M-136.2%
FY2021Dec 31, 2021$213.00M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$180.00M+318.6%
Q2 FY2026Jun 30, 2026$160.00M+122.2%
Q1 FY2026Mar 31, 2026$137.00M+107.6%
Q4 FY2025Dec 31, 2025$81.00M+76.1%
Q3 FY2025Sep 30, 2025$43.00M+22.9%
Q2 FY2025Jun 30, 2025$72.00M–
Q1 FY2025Mar 31, 2025$66.00M-12.0%
Q4 FY2024Dec 31, 2024$46.00M–
Q3 FY2024Sep 30, 2024$35.00M–
Q2 FY2024Jun 30, 2024-$118.00M–
Q1 FY2024Mar 31, 2024$75.00M–

More Supernus figures

See a number that looks wrong?